Chemoradiotherapy HNSCC, Randomized Study, Docetaxel,Cisplatin, 5FU,Erbitux. — 2007/02

Squamous Cell Head and Neck Carcinoma Clinical Trial

Official title:
A Phase III Randomized Multicenter Study,Comparing an Induction Chemotherapy Followed by Irradiation and Concurrent Erbitux Versus Chemoradiotherapy for Patients With Locoregional Advanced Head and Neck Cancers

Status Completed

Clinical Trial Summary

The purpose of this study is to demonstrate that induction chemotherapy followed by radiation therapy plus Cetuximab will give better results than the validated treatment (chemoradiotherapy), for treatment of locoregional advanced head and neck cancers.

Clinical Trial Description

Concurrent chemoradiotherapy (radiotherapy+ carboplatin + 5FU) is a validated treatment for patients with locoregional advanced head and neck cancers.

This study evaluates the outcome of induction chemotherapy (docetaxel, cisplatin, 5 FU) followed by radiation therapy + Erbitux for patients with head and neck carcinoma with almost one measurable lesion by RMI or CT scan.

We hope we can improve the progression free survival of 14% at two years . ;

Study Design

Related Conditions & MeSH terms

Squamous Cell Head and Neck Carcinoma

Clinical Trial Details

NCT number	NCT01233843
Study type	Interventional
Source	Groupe Oncologie Radiotherapie Tete et Cou
Contact
Status	Completed
Phase	Phase 3
Start date	May 18, 2009
Completion date	November 6, 2018

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT01289522` - Chemotherapy With Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	Phase 2
Withdrawn	`NCT03673735` - Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC	Phase 3
Completed	`NCT01268878` - Hematologic Toxicity Observation of the Docetaxel+ Cisplatin+ Fluorouracil (TPF)Medical Protocol	N/A
Terminated	`NCT00408252` - Efficacy of SU 011248 in Head And Neck Carcinoma	Phase 2